Cleveland Clinic | Strategic Alliance Partners

January 26, 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

January 26, 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

January 23, 2024

Danai Dima, MD, discusses the implications of real-world data derived from the MajesTEC-1 trial in pretreated patients with multiple myeloma.

January 19, 2024

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

January 19, 2024

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

January 12, 2024

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

January 12, 2024

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

January 12, 2024

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

January 04, 2024

Brian T. Hill, MD, PhD, discusses the final results from a phase 1/2 trial of carfilzomib given with R-CHOP in the frontline setting for patients with non-germinal center diffuse large B-cell lymphoma.

December 21, 2023

The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.

December 21, 2023

The panel discusses the Large Urology Group Practice Association and provides insights on collaborative care approaches in bladder cancer.

December 19, 2023

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

December 15, 2023

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

December 15, 2023

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

December 07, 2023

Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.

December 07, 2023

The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.

November 30, 2023

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

November 30, 2023

A panel of experts on bladder cancer provide an overview of the stratification, natural history, and treatment of bladder cancer.

November 28, 2023

New Cleveland Clinic research reveals how BRCA1 and BRCA2 gene mutations may impact cell communication in breast tissue, furthering the understanding of how cancer develops.

November 09, 2023

Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care, and the importance of confirming earlier post-hoc results from the VITAL trial in the AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.